Trial Profile
The influence of polymorphisms of metabolic enzymes and transporters on pharmacokinetics and clinical response to imatinib, dasatinib and nilotinib
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 May 2021
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Imatinib (Primary) ; Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Pharmacodynamics; Pharmacogenomic; Pharmacokinetics
- 07 Dec 2016 New trial record